[1]姚舜禹 罗素新 黄毕.心肌肌球蛋白抑制剂在梗阻性肥厚型心肌病治疗中的研究现状[J].心血管病学进展,2024,(5):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
　YAO Shunyu,LUO Suxin,HUANG Bi.Cardiac Myosin Inhibitors in Treatment of Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(5):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
点击复制

心肌肌球蛋白抑制剂在梗阻性肥厚型心肌病治疗中的研究现状()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年5期
页码:
397
栏目:
综述
出版日期:
2024-05-25

文章信息/Info

Title:
Cardiac Myosin Inhibitors in Treatment of Obstructive Hypertrophic Cardiomyopathy
作者:
姚舜禹 罗素新 黄毕
(重庆医科大学附属第一医院心血管内科,重庆400000)
Author(s):
YAO Shunyu; LUO Suxin; HUANG Bi
(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)
关键词:
梗阻性肥厚型心肌病; 心肌肌球蛋白抑制剂; 流出道梗阻; 短期预后
Keywords:
Obstructive h ypertrophic cardiomyopathy; Cardiac myosin inhibitors; Outflow tract obstruction; Short-term outcome
DOI:
10.16806/j.cnki.issn.1004-3934.2024.05.004
摘要:
梗阻性肥厚型心肌病（OHCM）是一种常染色体显性遗传病，以室间隔不对称性肥厚为主要表现，传统的治疗方法主要以改善症状为主，缺乏针对梗阻引起的血流动力学异常的特异性药物。随着对疾病研究的不断深入及药物研发的进展，针对梗阻性肥厚的病理生理学基础的药物——心肌肌球蛋白抑制剂应运而生。目前的试验结果表明，心肌肌球蛋白抑制剂可有效减轻左心室流出道梗阻，改善患者的纽约心功能分级和生活质量。该药的短期有效性和安全性已被证实，但长期的疗效目前尚在进行临床试验评估。现就心肌肌球蛋白抑制剂在OHCM中的作用机制并结合近期的临床试验结果及在未来OHCM中的治疗地位进行综述。
Abstract:
Obstructive h ypertrophic cardiomyopathy (OHCM) is an autosomal dominant genetic disease characterized by asymmetric hypertrophy of the interventricular septum. Traditional treatment methods mainly focus on improving symptoms and lack specific drugs for hemodynamic change caused by obstruction. With the deepening of research on the disease and the progress of drug development,drugs based on the pathophysiology of obstructive hypertrophy—Cardiac myosin inhibitors have emerged. Current experimental results show that cardiac myosin inhibitors can effectively reduce left ventricular outflow tract obstruction, improve patients’ New York Heart function assessment and quality of life. The short-term efficacy and safety of the drug have been confirmed,but the long-term efficacy is currently being evaluated in clinical trials. This article reviews the mechanism of cardiac myosin inhibitors in OHCM,combined with recent clinical trial results and the treatment status of OHCM in the future.

参考文献/References:

[1] Maron BJ,Rowin EJ,Maron MS. Global burden of hypertrophic cardiomyopathy[J]. JACC Heart Fail,2018,6(5):376-378.

[2] 国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志,2023,38(1):1-35.

[3] 中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组,中华心血管病杂志编辑委员会. 中国成人肥厚型心肌病诊断与治疗指南[J]. 中华心血管病杂志,2017,45(12):1015-1032 .

[4] Borjesson M,Pelliccia A. Incidence and aetiology of sudden cardiac death in young athletes:an international perspective[J]. Br J Sports Med,2009,43(9):644-648.

[5] Elliott PM,Anastasakis A,Borger MA,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2014,35(39):2733-2779.

[6] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol,2020,76(25):e159-e240.

[7] Chuang C,Collibee S,Ashcraft L,et al. Discovery of aficamten(CK-274),a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy[J]. J Med Chem,2021,64(19):14142-14152.

[8] Green EM,Wakimoto H,Anderson RL,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science,2016,351(6273):617-621.

[9] Semsarian C,Ingles J,Maron MS,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2015,65(12):1249-1254.

[10] Lehman SJ,Crocini C,Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies[J]. Nat Rev Cardiol,2022,19(6):353-363.

[11] Moore JR,Leinwand L,Warshaw DM. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor[J]. Circ Res,2012,111(3):375-385.

[12] Rohde JA,Roopnarine O,Thomas DD,et al. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin[J]. Proc Natl Acad Sci U S A,2018,115(32):E7486-E7494.

[13] Anderson RL,Trivedi DV,Sarkar SS,et al. Deciphering the super relaxed state of human ?β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115(35):E8143-E8152.

[14] Toepfer CN,Garfinkel AC,Venturini G,et al. Myosin sequestration regulates sarcomere function,cardiomyocyte energetics,and metabolism,informing the pathogenesis of hypertrophic cardiomyopathy[J]. Circulation,2020,141(10):828-842.

[15] Yotti R,Seidman CE,Seidman JG. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies[J]. Annu Rev Genomics Hum Genet,2019,20:129-153.

[16] Edelberg JM,Sehnert AJ,Mealiffe ME,et al. The impact of mavacamten on the pathophysiology of hypertrophic cardiomyopathy:a narrative review[J]. Am J Cardiovasc Drugs,2022,22(5):497-510.

[17] Stern JA,Markova S,Ueda Y,et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy[J]. PLoS One,2016,11(12):e168407.

[18] Chatur S,Hegde SM. Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy[J]. Curr Opin Cardiol,2023,38(5):424-432.

[19] Masri A,Olivotto I. Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy:addressing the core of the matter[J]. J Am Heart Assoc,2022,11(9):e24656.

[20] Heitner SB,Jacoby D,Lester SJ,et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy:a clinical trial[J]. Ann Intern Med,2019,170(11):741-748.

[21] Wheeler MT,Olivotto I,Elliott PM,et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption:a secondary analysis of the EXPLORER-HCM randomized trial[J]. JAMA Cardiol,2023,8(3):240-247.

[22] Saberi S,Cardim N,Yamani M,et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy:EXPLORER-HCM cardiac magnetic resonance substudy analysis[J]. Circulation,2021,143(6):606-608.

[23] Hegde SM,Lester SJ,Solomon SD,et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2021,78(25):2518-2532.

[24] Desai MY,Owens A,Geske JB,et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy[J]. J Am Coll Cardiol,2022,80(2):95-108.

[25] Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.

[26] Tian Z,Li L,Li X,et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy:the EXPLORER-CN randomized clinical trial[J]. JAMA Cardiol,2023,8(10):957-965.

[27] Squibb BM. A long-term safety extension study of mavacamten(MYK-461) in adults with hypertrophic cardiomyopathy who have completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) trials (MAVA-LTE):NCT03723655[EB/OL]. (2018-10-29)[2023-10-11]. https://clinicaltrials.gov/study/NCT03723655.

[28] Squibb BM . A phase 3,open-label,single arm,clinical study to evaluate efficacy,safety and tolerability of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy:NCT05414175[EB/OL]. (2022-06-10)[2023-10-11]. https://clinicaltrials.gov/study/NCT05414175.

[29] Maron MS,Masri A,Choudhury L,et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2023,81(1):34-45.

[30] Zhao X,Liu H,Tian W,et al. Safety,tolerability,pharmacokinetics,and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants:a randomized,double-blind,placebo-controlled,phase 1 study[J]. Front Pharmacol,2023,14:1227470.

[31] Cytokinetics. A phase 3,multi-center,randomized,double-blind,placebo-controlled trial to evaluate the efficacy and safety of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction:NCT05186818[EB/OL]. (2022-01-11)[2023-10-11]. https://clinicaltrials.gov/study/NCT05186818.

[32] Squibb BM . Announces data from EXPLORER-LTE demonstrating sustained improvements in clinically meaningful cardiovascular outcomes at weeks 48 and 84 in patients with symptomatic obstructive hypertrophic cardiomyopathy receiving mavacamten[EB/OL]. (2022-04-03)[2023-10-11]. https://news.bms.com/news/details/2022/Bristol-myers-squibb-announces-data-from-EXPLORER-LTE-demonstrating-sustained-improvements-in-clinically-meaningful-cardiovascular-outcomes-at-weeks-48-and-84-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-receiving-mavacamten/default.aspx.

[33] Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J,2023,44(37):3503-3626.

[34] Cytokinetics. A phase 3,multi-center,randomized,double-blind trial to evaluate the efficacy and safety of aficamten compared to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy[EB/OL]. (2023-03-14)[2023-10-11]. https://clinicaltrials.gov/study/NCT05767346.

[35] Li J ,Zhang J,Shi Y,et al. Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation[J]. Heart,2023,109(4):289-296.

相似文献/References:

[1]熊峰.梗阻性肥厚型心肌病治疗方法的现状与进展[J].心血管病学进展,2019,(6):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
　XIONG Feng.Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
[2]文琰 杨谋 胡宏德.梗阻性肥厚型心肌病缓解梗阻的治疗进展[J].心血管病学进展,2022,(9):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
　WEN Yan,YANG Mou,HU Hongde.Obstruction Relief Therapy in Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(5):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
[3]徐克 孙阳 汪道文.梗阻性肥厚型心肌病的介入和外科手术治疗及进展[J].心血管病学进展,2024,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
　XU Ke,SUN Yang,WANG Daowen?/html>.New Perspectives on Interventional and Surgical Treatment for?bstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(5):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
[4]李莎 严霜霜 熊峰.Mavacamten在肥厚型心肌病中的治疗进展[J].心血管病学进展,2024,(10):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]
　LI ShaYAN ShuangshuangXIONG Feng.Advances In the Treatment Of Mavacamten?n Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(5):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]

更新日期/Last Update: 2024-06-28